PPN/EPN BD tool

EMA + FDA approved EU EMA-only US FDA-only ★ PPN Partner ★★ 2025–2026 New Orphan designated

🔧 Data Tools · TR data quality: — of — verified Verification chip on every product's expanded view shows last TITCK source & date · PDF button works offline (uses browser print dialog when CDN unreachable)

Search

Clinical

Therapeutic Area

Approval Period

Approval Agency

Orphan Status

Commercial

PPN Partner

BD Stage

TR YDIL Status

Min Criticality

Network Coverage

TR YDIL Status: On YDIL — import without per-patient TİTCK approval ⭐Fast-track — no additional TİTCK written approval needed (Sheet 2) Individual application — 3-physician council + TİTCK review per patient New — not on YDIL; new TİTCK pathway required ✓ Verified against TİTCK YDIL Excel dated 28/04/2026

🗺 Map — company HQ locations for planning regional roadtrips. Green = you have contacts (Network), amber = PPN partner, blue = target. Click a pin for score, contacts and a one-pager. Clusters group nearby HQs — click to zoom in.

📅 BD event calendar — annual timeline of partnering conventions and scientific congresses. ★★★ primary BD venues (BIO, J.P. Morgan, BIO-Europe, WODC) are the priority targets for meetings; ★★ scientific congresses are for KOL/medical engagement. Past events are dimmed.

📥 Wishlist → Target Companies · upload a molecule wishlist from a territory (Excel/CSV) and get, for every molecule, the candidate manufacturers PPN can approach — each tagged with reference-agency MA fit (EU/FDA/WHO-PQ = COFEPRIS-reliance eligible), entry angle, home country, and Turkish eligibility.

Molecules not yet in our swept pool are flagged so they can be swept and added.

📄

Drop a wishlist file here or tap to choose

Excel (.xlsx/.xls) or CSV — the molecule column is detected automatically

🇲🇽 Mexico — Promising-Tender Target Scanner · high-value molecules across Mexican public tenders — national (federal Compra Consolidada · IMSS-Bienestar / Birmex) and local (state health secretariats · ISSSTE · municipal) — mapped to the companies PPN can actually register.

Registration model differs from the Balkans: Mexico runs on the COFEPRIS equivalence / reliance route (in force 29 Aug 2025) — a product already authorised by a recognised reference authority (ICH members: FDA, EMA, PMDA, Health Canada, Swissmedic…, WHO-listed authorities, or WHO-PQ for generics) qualifies for an abbreviated ~45-business-day review. PPN acts as the Mexican titular de registro + local importer. So targets are ranked by registration fit — does the holder carry a qualifying reference-agency MA — not by an EU-register cascade.

🌍→🇲🇽 Supply-partner targets: PPN brings a reference-agency-approved manufacturer (EU MA / FDA / WHO-PQ) into Mexico under the COFEPRIS equivalence route, acting as titular de registro + importer — the target is any globally-approved maker without a Mexican entity, especially EU-MA holders whose product meets the equivalence criteria. Turkish manufacturers are the fast-access lane (TITCK is an ICH regulatory member since 2020), but not the only scope. See 🎯 Target Opportunities for the molecule-by-molecule addressable prize and entry angle.

registration-fit holders only

🇮🇶 Iraq — KIMADIA Tender Demand Scanner · high-value molecules across Iraqi public procurement. Iraq runs largely through KIMADIA (the MoH central drug-buying company) via consolidated federal tenders, with the Kurdistan region (KRG) procuring separately and a private-sector channel through registered scientific bureaus / agents.

Registration route: products are registered with the Iraqi MoH / KIMADIA (and separately with KRG-MoH); PPN acts as/through a local registered agent (scientific bureau). Targets are ranked by modeled tender demand.

⚠ Scaffold with SEED data. These molecules and values are placeholders to stand up the tab. The KIMADIA / MoH tender scan will verify and replace them with confirmed awards, winners and prices.

🇷🇺 Russia — Early-Access & Tech-Transfer Intelligence · Russia is an NPP early-access market for PPN, not a tender-registration one. From 2025, import-substitution strongly favours domestic/EEU-made product — where ≥1 domestic bid exists, foreign product is effectively excluded — so tech transfer / localization is the realistic route in.

⚠ Not a live award scanner. Russia publishes no accessible per-molecule award/price feed (EIS = raw XML dumps; analytics are paid, OKPD2-coded not by INN). Below is curated market intelligence — molecule market sizes + competition — for the priority (Bio-Thera) molecules, from public analytics. Figures are market ceilings, not addressable revenue.

🇩🇿 Algeria — Two Access Channels · Market ≈ $4.0B local production (2024) vs a falling ~$1.0B import bill. Regulator ANPP registers; PCH procures for public hospitals; MIP drives import-substitution.

① Registered market — products with an Algerian MA. Import-substitution: once a molecule is made/packaged locally, import is banned (~357 products). PPN play: register + local packaging so it counts as local. · ② Rare-disease / ATU — the "rare disease" program is really an unregistered-drug supply route: Autorisation Temporaire d'Utilisation (Health Law 18-11 art.233), imported via PCH with price negotiated directly, dispensed free. PPN play: named-patient supply of unregistered innovator/orphan molecules.

🎯 Deal Flow — the whole BD pipeline in one place across 🇹🇷🇷🇺🇩🇿 Turkey · Russia · Algeria + 🇲🇰 Non-EU Balkans: the funnel at a glance, what to act on now, and the full board. The lead filter below focuses all three on your companies.

▾📊 Funnel — pipeline at a glance, who leads what, what needs attention

▾⚡ Do next — urgent nudges + auto-drafted multi-step plans, most urgent first

▾📋 Board — drag a company through the stages; 🇹🇷🇷🇺🇩🇿 + 🇲🇰 cards share columns; red border = stalled 21+ days

▸✅ Signed — live book of business; the closed end of the pipeline (TR-mfr outbound tagged)

Loading NPP lane…

🤝 Network — companies where at least one of the three of you has a contact. Ranked by company score (unscored companies sink to the bottom). Click a row for products; download an editable Word one-pager.

🎯 Targets — companies you have no contact at yet. Same scoring; upload your LinkedIn connections to move companies into Network as your reach grows.

🇲🇰 Non-EU Balkans — Target Scanner · North Macedonia → Albania → Kosovo. Separate operating model from the Turkey NPP business: PPN acts as Marketing Authorization Holder (PPM) or as distributor. Targets are B2B dossier / license-and-supply houses (Adalvo, Synthon type) and EU manufacturers holding their own EU MAs willing to share marketed CPPs. Registration cascade: register in NMK first → obtain marketed CPP → file in AL & XK.

🏢 EU-MA Company Targeting — for each tendered Balkan molecule, who holds an EU marketing authorisation, split by originator · global generic · local-regional. Sourced from national registers (Spain · France · Latvia · Lithuania · Finland · Sweden) + EMA-central. Local/regional holders are the most partner-receptive for the NMK→AL→XK expansion.

has local/regional holder min €M

🌍 EU MA-Holder Targets — molecule-first prioritisation. Tri-market (NMK · AL · XK) molecules ranked by revenue potential, mapped to whoever holds their EU marketing authorisation — centrally (originator) or at member-state level — across the full register universe (EMA + 13 national registers). Companies = EU MA holders ranked by addressable Balkan revenue + breadth; Molecules = each molecule → its EU MA holder(s); Local distributors = in-market MA holders for distributorship deals. Revenue figures = awarded / realized public-procurement (tender) value over the dynamic window since 1 Jan 2024 to today (expands as new tender data lands), at award-time prices. The €/yr line under each total annualizes it on that same live window, so demand and the (annual) reimbursement basis are on one footing. Caveat: this is a trailing tender proxy — molecules dispensed mainly at retail/outpatient on reimbursement rather than via tenders are under-represented.

min €M

💎 Whitespace → Partner — molecules from the euMol prospect catalogues (the EU-MA houses we've mapped) cross-referenced against Balkan tender demand, filtered to whitespace (not registered in Albania and not on the Kosovo register). TENDER lane = live open-tender demand; NPP lane = specialty/rare held in catalogue with no tender footprint (named-patient play). Computed live from the euMol arrays × the tri-market demand view.

whitespace only (absent AL & XK) min €k

Products you've dropped from active pursuit. Click Restore to move back to Pipeline.

Drop product from pipeline

Activity notes

Outreach email draft